Loading…
Loading…
ISCO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ISCO and 80,000+ other tickers.
See exactly how ISCO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ISCO and 80,000+ other tickers.
International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products derived from its proprietary human parthenogenetic stem cells, a unique form of pluripotent stem cells. ISCO is actively engaged in developing specialized cell types, such as neural stem cells, which hold promise for treating Parkinson's disease and other disorders affecting the central nervous system. Beyond therapeutics, the company also…
International Stem Cell Corp. (OTCMKTS:ISCO - Get Free Report)'s stock price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $0.15 and traded as high as $0.17. International Stem Cell shares last traded at $0.17, with a volume of 302 shares trading hands. International Stem
International Stem Cell Corp. (OTCMKTS:ISCO - Get Free Report)'s stock price passed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.14 and traded as high as $0.1761. International Stem Cell shares last traded at $0.1640, with a volume of 42,542 shares changing hands. International Stem
International Stem Cell Corp. (OTCMKTS:ISCO - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 9,559 shares, a growth of 24,410.3% from the January 15th total of 39 shares. Based on an average daily trading volume, of
International Stem Cell Corp. (OTCMKTS:ISCO - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 30th, there was short interest totaling 9,559 shares, a growth of 24,410.3% from the January 15th total of 39 shares. Based on an average daily trading volume, of
International Stem Cell Corp. (OTCMKTS:ISCO - Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 39 shares, a growth of 21.9% from the December 31st total of 32 shares. Currently, 0.0% of the company's shares are short sold. Based on